HK1113542A1 - Use of l-carnitine and glucose for the treatment of cardiovascular diseases l- - Google Patents
Use of l-carnitine and glucose for the treatment of cardiovascular diseases l-Info
- Publication number
- HK1113542A1 HK1113542A1 HK08102916.9A HK08102916A HK1113542A1 HK 1113542 A1 HK1113542 A1 HK 1113542A1 HK 08102916 A HK08102916 A HK 08102916A HK 1113542 A1 HK1113542 A1 HK 1113542A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- carnitine
- glucose
- treatment
- infarction
- grams
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
- 239000008103 glucose Substances 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title 1
- 229960001518 levocarnitine Drugs 0.000 title 1
- 206010061216 Infarction Diseases 0.000 abstract 2
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000346A ITRM20040346A1 (it) | 2004-07-13 | 2004-07-13 | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| PCT/EP2005/006657 WO2006005415A2 (en) | 2004-07-13 | 2005-06-21 | Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1113542A1 true HK1113542A1 (en) | 2008-10-10 |
Family
ID=34971575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08102916.9A HK1113542A1 (en) | 2004-07-13 | 2008-03-13 | Use of l-carnitine and glucose for the treatment of cardiovascular diseases l- |
| HK12106717.5A HK1166003A1 (zh) | 2004-07-13 | 2012-07-10 | -肉鹼和葡萄糖治療心血管疾病的應用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12106717.5A HK1166003A1 (zh) | 2004-07-13 | 2012-07-10 | -肉鹼和葡萄糖治療心血管疾病的應用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7879908B2 (el) |
| EP (1) | EP1773314B1 (el) |
| JP (1) | JP5230195B2 (el) |
| KR (1) | KR101296479B1 (el) |
| CN (2) | CN101087602B (el) |
| AT (1) | ATE542529T1 (el) |
| AU (1) | AU2005262050B2 (el) |
| BR (1) | BRPI0513303A8 (el) |
| CA (1) | CA2569888C (el) |
| CY (1) | CY1112686T1 (el) |
| DK (1) | DK1773314T3 (el) |
| ES (1) | ES2380913T3 (el) |
| HK (2) | HK1113542A1 (el) |
| HR (1) | HRP20120178T1 (el) |
| IT (1) | ITRM20040346A1 (el) |
| ME (1) | ME01345B (el) |
| MX (1) | MXPA06014665A (el) |
| PL (1) | PL1773314T3 (el) |
| PT (1) | PT1773314E (el) |
| RS (1) | RS52253B (el) |
| SI (1) | SI1773314T1 (el) |
| WO (1) | WO2006005415A2 (el) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| JPS6415220A (en) | 1987-07-06 | 1989-01-19 | Mitsubishi Electric Corp | Tension control device for utilizing maximum torque and maximum electric current of winding motor |
| JPH06102624B2 (ja) * | 1990-08-10 | 1994-12-14 | アース製薬株式会社 | 非心臓由来の不整脈防止薬 |
| IT1261695B (it) * | 1993-06-02 | 1996-05-29 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono. |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| EP1133289A1 (en) * | 1998-11-26 | 2001-09-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
| WO2001026649A1 (en) * | 1999-10-11 | 2001-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| ATE551317T1 (de) * | 2002-04-01 | 2012-04-15 | Univ Alberta | Verbindungen, die die glucosenutzung stimulieren, und anwendungsverfahren |
| ITRM20030178A1 (it) * | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
-
2004
- 2004-07-13 IT IT000346A patent/ITRM20040346A1/it unknown
-
2005
- 2005-06-21 MX MXPA06014665A patent/MXPA06014665A/es not_active Application Discontinuation
- 2005-06-21 AU AU2005262050A patent/AU2005262050B2/en not_active Ceased
- 2005-06-21 AT AT05755616T patent/ATE542529T1/de active
- 2005-06-21 CN CN2005800234751A patent/CN101087602B/zh not_active Expired - Fee Related
- 2005-06-21 BR BRPI0513303A patent/BRPI0513303A8/pt not_active Application Discontinuation
- 2005-06-21 SI SI200531481T patent/SI1773314T1/sl unknown
- 2005-06-21 PL PL05755616T patent/PL1773314T3/pl unknown
- 2005-06-21 KR KR1020077000711A patent/KR101296479B1/ko active IP Right Grant
- 2005-06-21 RS RS20120095A patent/RS52253B/en unknown
- 2005-06-21 ES ES05755616T patent/ES2380913T3/es active Active
- 2005-06-21 EP EP05755616A patent/EP1773314B1/en active Active
- 2005-06-21 JP JP2007520688A patent/JP5230195B2/ja not_active Expired - Fee Related
- 2005-06-21 CN CN201110226409.1A patent/CN102349923B/zh not_active Expired - Fee Related
- 2005-06-21 CA CA2569888A patent/CA2569888C/en active Active
- 2005-06-21 WO PCT/EP2005/006657 patent/WO2006005415A2/en active Application Filing
- 2005-06-21 PT PT05755616T patent/PT1773314E/pt unknown
- 2005-06-21 US US11/629,202 patent/US7879908B2/en active Active
- 2005-06-21 DK DK05755616.9T patent/DK1773314T3/da active
- 2005-06-21 ME MEP-2012-32A patent/ME01345B/me unknown
-
2008
- 2008-03-13 HK HK08102916.9A patent/HK1113542A1/xx not_active IP Right Cessation
-
2010
- 2010-12-20 US US12/972,617 patent/US8394854B2/en active Active
-
2012
- 2012-02-22 HR HRP20120178TT patent/HRP20120178T1/hr unknown
- 2012-04-05 CY CY20121100341T patent/CY1112686T1/el unknown
- 2012-07-10 HK HK12106717.5A patent/HK1166003A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaspan et al. | Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| HK1166003A1 (zh) | -肉鹼和葡萄糖治療心血管疾病的應用 | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| Lappa et al. | Successful treatment of a complicated case of neuroleptic malignant syndrome | |
| JP4381685B2 (ja) | ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用 | |
| MXPA05007612A (es) | Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. | |
| ES2281775T3 (es) | Metodo para tratar insuficiencia renal. | |
| Poole-Wilson | Timolol maleate (MK 950) in the treatment of essential hypertension | |
| JP2006045200A (ja) | 間質性膀胱炎の治療薬 | |
| JP2008517872A5 (el) | ||
| McDaniel | Antidepressant activity of linezolid | |
| Ayache et al. | Methylphenidate in a patient with depression and respiratory insufficiency | |
| Prabhu et al. | Digital gangrene due to dopamine infusion-a case report | |
| Olgar et al. | Prolonged supine hypertension due to midodrine use in an orthostatic hypotensive child | |
| József Simkó et al. | Sinus node dysfunction due to psychotropic agents combination | |
| Goldberg, B., Levin, NW, Rubinstein, A. & Cohen | Alpha-methyldopa in hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230619 |